These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 24564719)

  • 1. Structural analysis of the novel influenza A (H7N9) viral Neuraminidase interactions with current approved neuraminidase inhibitors Oseltamivir, Zanamivir, and Peramivir in the presence of mutation R289K.
    Tran-To Su C; Ouyang X; Zheng J; Kwoh CK
    BMC Bioinformatics; 2013; 14 Suppl 16(Suppl 16):S7. PubMed ID: 24564719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population.
    Yen HL; McKimm-Breschkin JL; Choy KT; Wong DD; Cheung PP; Zhou J; Ng IH; Zhu H; Webby RJ; Guan Y; Webster RG; Peiris JS
    mBio; 2013 Jul; 4(4):. PubMed ID: 23860768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of substitutions in the neuraminidase of A(H7N9) influenza viruses selected following serial passage in the presence of different neuraminidase inhibitors.
    Farrukee R; Butler J; Reading PC; Hurt AC
    Antiviral Res; 2019 Aug; 168():68-75. PubMed ID: 31132385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational assay of H7N9 influenza neuraminidase reveals R292K mutation reduces drug binding affinity.
    Woods CJ; Malaisree M; Long B; McIntosh-Smith S; Mulholland AJ
    Sci Rep; 2013 Dec; 3():3561. PubMed ID: 24356381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug Susceptibility Evaluation of an Influenza A(H7N9) Virus by Analyzing Recombinant Neuraminidase Proteins.
    Gubareva LV; Sleeman K; Guo Z; Yang H; Hodges E; Davis CT; Baranovich T; Stevens J
    J Infect Dis; 2017 Sep; 216(suppl_4):S566-S574. PubMed ID: 28934455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic behavior of avian influenza A virus neuraminidase subtype H5N1 in complex with oseltamivir, zanamivir, peramivir, and their phosphonate analogues.
    Udommaneethanakit T; Rungrotmongkol T; Bren U; Frecer V; Stanislav M
    J Chem Inf Model; 2009 Oct; 49(10):2323-32. PubMed ID: 19780597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Silico Studies Reveal Peramivir and Zanamivir as an Optimal Drug Treatment Even If H7N9 Avian Type Influenza Virus Acquires Further Resistance.
    Sarukhanyan E; Shanmugam TA; Dandekar T
    Molecules; 2022 Sep; 27(18):. PubMed ID: 36144655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the R292K Mutation on Influenza A (H7N9) Virus Resistance towards Peramivir: A Molecular Dynamics Perspective.
    Mtambo SE; Ugbaja SC; Kumalo HM
    Molecules; 2022 Mar; 27(5):. PubMed ID: 35268746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs.
    Fujisaki S; Takashita E; Yokoyama M; Taniwaki T; Xu H; Kishida N; Sato H; Tashiro M; Imai M; Odagiri T
    Biochem Biophys Res Commun; 2012 Dec; 429(1-2):51-6. PubMed ID: 23131559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insights into susceptibility of antiviral drugs against the E119G mutant of 2009 influenza A (H1N1) neuraminidase by molecular dynamics simulations and free energy calculations.
    Pan P; Li L; Li Y; Li D; Hou T
    Antiviral Res; 2013 Nov; 100(2):356-64. PubMed ID: 24055835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermolecular Mechanism and Dynamic Investigation of Avian Influenza H7N9 Virus' Susceptibility to E119V-Substituted Peramivir-Neuraminidase Complex.
    Mtambo SE; Ugbaja SC; Mushebenge AG; Abubakar BH; Ntuli ML; Kumalo HM
    Molecules; 2022 Mar; 27(5):. PubMed ID: 35268741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Profiling and characterization of influenza virus N1 strains potentially resistant to multiple neuraminidase inhibitors.
    Baek YH; Song MS; Lee EY; Kim YI; Kim EH; Park SJ; Park KJ; Kwon HI; Pascua PN; Lim GJ; Kim S; Yoon SW; Kim MH; Webby RJ; Choi YK
    J Virol; 2015 Jan; 89(1):287-99. PubMed ID: 25320319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergence of H7N9 Influenza A Virus Resistant to Neuraminidase Inhibitors in Nonhuman Primates.
    Itoh Y; Shichinohe S; Nakayama M; Igarashi M; Ishii A; Ishigaki H; Ishida H; Kitagawa N; Sasamura T; Shiohara M; Doi M; Tsuchiya H; Nakamura S; Okamatsu M; Sakoda Y; Kida H; Ogasawara K
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4962-73. PubMed ID: 26055368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral susceptibility of avian and swine influenza virus of the N1 neuraminidase subtype.
    Stoner TD; Krauss S; DuBois RM; Negovetich NJ; Stallknecht DE; Senne DA; Gramer MR; Swafford S; DeLiberto T; Govorkova EA; Webster RG
    J Virol; 2010 Oct; 84(19):9800-9. PubMed ID: 20660186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel pyrosequencing assay for the detection of neuraminidase inhibitor resistance-conferring mutations among clinical isolates of avian H7N9 influenza virus.
    Qi Y; Fan H; Qi X; Zhu Z; Guo X; Chen Y; Ge Y; Zhao K; Wu T; Li Y; Shan Y; Zhou M; Shi Z; Wang H; Cui L
    Virus Res; 2014 Jan; 179():119-24. PubMed ID: 24211668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Drug susceptibility of wild-type and mutant H7N9 neuraminidase to zanamivir and oseltamivir].
    Wei YN; Zhang C; Chen Q; Guo Y
    Bing Du Xue Bao; 2014 Jul; 30(4):396-401. PubMed ID: 25272593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility.
    Hai R; Schmolke M; Leyva-Grado VH; Thangavel RR; Margine I; Jaffe EL; Krammer F; Solórzano A; García-Sastre A; Palese P; Bouvier NM
    Nat Commun; 2013; 4():2854. PubMed ID: 24326875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
    Oakley AJ; Barrett S; Peat TS; Newman J; Streltsov VA; Waddington L; Saito T; Tashiro M; McKimm-Breschkin JL
    J Med Chem; 2010 Sep; 53(17):6421-31. PubMed ID: 20695427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced susceptibility to all neuraminidase inhibitors of influenza H1N1 viruses with haemagglutinin mutations and mutations in non-conserved residues of the neuraminidase.
    McKimm-Breschkin JL; Williams J; Barrett S; Jachno K; McDonald M; Mohr PG; Saito T; Tashiro M
    J Antimicrob Chemother; 2013 Oct; 68(10):2210-21. PubMed ID: 23759505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to Mutant Group 2 Influenza Virus Neuraminidases of an Oseltamivir-Zanamivir Hybrid Inhibitor.
    Wu Y; Gao F; Qi J; Bi Y; Fu L; Mohan S; Chen Y; Li X; Pinto BM; Vavricka CJ; Tien P; Gao GF
    J Virol; 2016 Dec; 90(23):10693-10700. PubMed ID: 27654293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.